

U.S. Pharmacogenomics Market Size to Achieve USD 5,676.1 Million by 2031, Fueled by a CAGR of 8.7%: Says AMR

Pharmacogenomics, also known as pharmacogenetics, is a branch of genomic medicine that uses a patient's genetic makeup to customize medications they receive.

PORTLAND, OR, UNITED STATES, March 11, 2025 /EINPresswire.com/ -- The U.S. pharmacogenomics market is experiencing significant growth due to several driving factors. Firstly, advancements in genomic research and technology have enabled personalized medicine approaches,



U.S. Pharmacogenomics Market Future

which utilize genetic information to determine the most effective treatments for individuals. This has increased the demand for pharmacogenomics testing and analysis. Secondly, growing awareness among healthcare professionals and patients about the potential benefits of pharmacogenomics in optimizing drug therapy is driving adoption. Additionally, the rising prevalence of chronic diseases and the need for more targeted therapies further fuel the market growth. Moreover, supportive government initiatives, increasing investment in research and development, and collaborations between pharmaceutical companies and research institutions are contributing to the market expansion.

Allied Market Research has published a study report with the title U.S. Pharmacogenomics Market Size was valued at USD 2,463.9 Million in 2021 and is Anticipated to reach USD 5,676.1 Million by 2031, registering a CAGR of 8.7% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

https://www.alliedmarketresearch.com/request-sample/47832

- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN
- · Agilent Technologies, Inc.
- Eurofins Scientific
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Becton, Dickinson and Company
- Myriad Genetics, Inc.

The pharmacogenomics market can be segmented based on technology, application, end-user, and region. Here's a brief overview:

By Technology

- Next Generation Sequencing
- Polymerase Chain Reaction
- Gel Electrophoresis
- Mass Spectrometry
- Microarray
- Others

By Application

- Cardiovascular Diseases
- Infectious Diseases
- Oncology
- Neurological Diseases
- Psychiatry
- Others

By End User

- Hospitals & Clinics
- Research Institutions
- Academic Institutes

Key Findings Of Study

- By technology, the polymerase chain reaction segment was the highest contributor to the U.S. Pharmacogenomics Market in 2021.
- Depending on application, the oncology segment dominated the U.S. Pharmacogenomics Market in 2021, and is expected to continue this trend during the forecast period.
- Depending on end user, the hospitals & clinic segment dominated the market in 2021, and is expected to continue this trend during the forecast period.

Our Market Research Solution Provides You Answer to Below Mentioned Question:

- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- · What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?

By Region Outlook

North America

(U.S., Canada, Mexico)

Europe

(Germany, France, UK, Italy, Spain, Rest of Europe)

Asia-Pacific

(Japan, China, India, Rest of Asia-Pacific)

LAMEA

(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022

help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+15038946022 ext.
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/792780568

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.